AI in healthcare stocks

NVIDIA directly supplies BioNeMo and DGX Cloud infrastructure for model training and inference in drug discovery, making EDEN training a direct workload opportunity.

Addresses the 'Eroom's Law' bottleneck in pharma R&D by using AI to predict candidate success.

Revenue is tied to drug milestones and success of candidates identified by AI platforms.

Uses AI-powered operating systems for mapping but focus has historically been on high-throughput screening rather than autonomous competitive agents.

Recursion leverages AI to accelerate drug discovery, significantly reducing R&D costs and time-to-market for new therapeutic candidates, transforming the traditional biotech model.

Insilico is a listed generative-AI drug-discovery company positioned to use and commercialize advanced biology models.

InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services. Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and other therapeutic areas. The company is also involved in research and development collaboration, software solutions, business development, new drug discovery, and holding company businesses. The company has a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd. for the development of oligonucleotide therapeutics; and strategic collaboration with Human Life Foundation Models, Inc. for the development of foundation models for human longevity science. It operates in Hong Kong, the United States, the United Kingdom, Kingdom of Saudi Arabia, Japan, Denmark, the United Arab Emirates, Korea, Mainland China, Germany, Switzerland, Taiwan, and internationally. The company was founded in 2014 and is based in New Territories, Hong Kong.

Absci is a public generative-AI drug-creation company competing for pharmaceutical partnerships, customers, talent, and capital.

Absci is a generative AI drug-creation company competing directly for pharmaceutical platform partnerships and customers.

Siemens is the prime awardee developing an autonomous endovascular surgical system with robotic catheter control and learning-based navigation.

Siemens Healthineers is the prime recipient of up to $31.1 million to develop an autonomous endovascular surgical system. The award funds a platform combining robotic catheter control, autonomy-optimized devices, fluoroscopy, and reinforcement-learning navigation, while preserving compatibility with Siemens’ existing non-autonomous product line. Successful milestones could create new robotic-system revenue, strengthen Siemens’ neurovascular and imaging ecosystem, and increase utilization of related capital equipment.

eyonis is Median’s AI-powered Software as a Medical Device platform, and the review could provide dedicated capital for U.S. lung-screening commercialization.

Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.

Tempus acquired Paige, a digital-pathology AI platform, placing it in the same consolidating AI pathology layer as Proscia.

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Nano-X directly owns the affected AI-imaging commercialization pathway through Nanox.AI's HealthOST Bone Solution, which analyzes routine CT scans for musculoskeletal disease.

Lunit Inc., established in 2013 and headquartered in Seoul, South Korea, develops and supplies advanced artificial intelligence software solutions aimed at improving cancer screening, diagnosis, and treatment. The company's portfolio includes AI-powered tools for analyzing medical images like chest X-rays and mammograms, as well as intelligent biomarkers for immune phenotyping and precise PD-L1 quantification, which are vital for optimizing immunotherapy.

Vuno Inc. specializes in developing artificial intelligence solutions for the medical industry. The company's AI-driven offerings are designed to analyze diverse medical data, providing crucial assistance in diagnosing various diseases. Its comprehensive product suite includes BoneAge, an AI software for assessing bone age; DeepBrain, a quantitative brain parcellation tool for analyzing neurodegenerative and other neurological conditions; an AI-powered diagnostic support system for detecting abnormalities in chest X-rays; Fundus AI, an AI-based screening solution for retinal irregularities; and LungCT AI, which focuses on detecting and reporting pulmonary lung nodules. Established in 2014, the company is headquartered in Seoul, South Korea.

JLK, Inc., a South Korean enterprise, provides artificial intelligence-powered solutions to aid in patient diagnostics. The company's offerings span both AI medical and AI security applications. Its advanced AI platform delivers real-time, on-site services, integrating effortlessly with hospital infrastructure to fulfill the diagnostic needs of healthcare professionals. JLK's medical segment addresses a diverse array of conditions, supporting their management, treatment, and overall service. This includes a significant focus on neurological disorders like ischemic stroke, hemorrhagic stroke, brain aneurysm, and Alzheimer's disease. Furthermore, the company extends its capabilities to lung diseases, coronary artery disease, prostate cancer, and digital pathology. Formerly known as JLK INSPECTION Co.,Ltd., JLK, Inc. is headquartered in Cheongju, South Korea.

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation; and delivers a binary prediction on the wounds capacity to heal or not heal by a specified time point in the future to assist the physician in making a more accurate, timely, and informed decision regarding the treatment of the patient’s wounds. Its system also includes MSI imaging technology, which consists of proprietary multi-spectral optics and sensors that capture injured tissue images; and AI-Burn software. Spectral AI, Inc. is headquartered in Dallas, Texas.

SOPHiA GENETICS S.A. operates as a specialized company within the healthcare technology sector. The firm provides the SOPHiA DDM platform, a cloud-native Software-as-a-Service (SaaS) solution engineered to analyze diverse multimodal datasets and various diagnostic inputs, thereby extracting valuable insights. This platform, together with its related offerings and services, is widely adopted by hospitals, laboratories, and biopharmaceutical organizations across the globe. Founded in 2011, SOPHiA GENETICS S.A. is headquartered in Saint-Sulpice, Switzerland.

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Hoffman's transition to a biopharma AI startup highlights the growing maturity and competitive interest in the computational biology space. This serves as a fundamental catalyst for Schrödinger, which integrates physics-based modeling with machine learning to improve predictive accuracy in molecular design.

ContextVision AB (publ), a medical technology enterprise established in Stockholm, Sweden, in 1983, delivers sophisticated software solutions. The firm specializes in image analysis and artificial intelligence, supplying these advanced technologies to original equipment manufacturers (OEMs) across Asia, Europe, and the United States. Their comprehensive product suite is designed to optimize image quality across various medical imaging modalities, including two-dimensional, three-dimensional, and four-dimensional ultrasound, radiography, magnetic resonance imaging (MRI), and mammography. Key offerings include: Rivent: Provides superior image quality for a broad spectrum of ultrasound applications such as women's health, general imaging, cardiovascular, and point-of-care. VolarView: An image enhancement software specifically developed for the burgeoning handheld ultrasound market. GOPiCE: A proprietary technology enabling real-time volumetric image enhancement. Altumira/Altumira Plus: A robust platform for digital radiography. An Orthopedic Package: Tailored for specialized orthopedic imaging needs. GOPView MRI2Plus: An advanced solution for MRI image improvement. INIFY Prostate Screening: Offers digital analysis for prostate biopsies.

Based in Lund, Sweden, Qlucore AB (publ) delivers advanced bioinformatics data analysis tools for global application in both scientific research and accurate medical diagnostics. Its product suite includes Qlucore Omics Explorer, an AI-powered bioinformatics software designed for research across various sectors such as life science, biotechnology, food, plant industries, and academia. Additionally, the company offers Qlucore Diagnostics, a specialized software platform for multi-omics companion and precision diagnostics, as well as Qlucore Insights, which facilitates the analysis of clinical data. Qlucore was established in 2007.

Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.

Evogene Ltd. is a computational biology firm specializing in the identification and advancement of products across human health and agricultural sectors. Its proprietary Computational Predictive Biology (CPB) platform leverages deep biological insights, big data, and artificial intelligence to precisely uncover and guide the creation of life science solutions, including novel microbes, small molecules, and genetic components. The company operates through distinct divisions: Agriculture, Human Health, and Industrial Applications. The Agriculture division concentrates on improving crop performance through the development of advanced seed traits, agricultural chemicals, and biological products for crops like corn, soybean, wheat, rice, and cotton. The Human Health division focuses on pioneering microbiome-based treatments for conditions such as immuno-oncology, gastrointestinal ailments, and antibiotic-resistant infections, and also offers medical cannabis products. The Industrial Applications segment is dedicated to developing improved castor bean varieties for various industrial feedstock requirements. Evogene has a global footprint, conducting business in the United States, Israel, Brazil, and other international markets. It maintains significant partnerships, including agricultural collaborations with BASF SE, Corteva, and Bayer, and a medical cannabis development agreement with Cannbit Ltd. through its subsidiary, Canonic Ltd. Established in 1999, Evogene Ltd. is headquartered in Rehovot, Israel.

BullFrog AI Holdings, Inc., along with its affiliated entities, functions as an advanced digital biopharmaceutical firm. Its core mission involves harnessing artificial intelligence and machine learning (AI/ML) to process and interpret extensive medical and healthcare datasets specifically within the United States. A central offering is bfLEAP, a proprietary AI/ML platform meticulously crafted for the thorough examination of both preclinical and clinical research data. The company has also secured critical intellectual property through licensing agreements. One such accord, with George Washington University, provides rights to utilize siRNA targeting Beta2-spectrin. This technology is being investigated for its therapeutic potential across a spectrum of human conditions, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). Additionally, a partnership with Johns Hopkins University grants access to a distinct Mebendazole formulation, developed for the treatment of various human cancers or neoplastic diseases. Founded in 2017, BullFrog AI Holdings, Inc. operates from its headquarters in Gaithersburg, Maryland.

Healthcare Triangle, Inc. (HCTI) is a technology firm dedicated to the healthcare sector, specializing in crafting innovative solutions across cloud services, data science, and professional and managed IT support. The company provides a comprehensive array of software, platforms, and services designed to empower healthcare and pharmaceutical organizations. These offerings help facilitate personalized treatment plans, accelerate precision medicine initiatives, drive innovation in drug discovery and development, foster collaborative research efforts, enable evidence-based decision-making, and streamline digital transformation. Among its proprietary software offerings are CloudEz, an enterprise platform streamlining multi-cloud migration and oversight, allowing clients to unify management of their private, hybrid, and public cloud environments. Another key platform is DataEz, a cloud-native solution providing robust data analytics and scientific data processing capabilities tailored for the life sciences, pharmaceutical, and healthcare provider sectors. Additionally, the company offers Readabl.AI, a Software-as-a-Service (SaaS) solution leveraging public cloud-based artificial intelligence and machine learning to intelligently identify and extract vital healthcare data from diverse documents such as faxes and narrative reports. Beyond its platforms, Healthcare Triangle delivers a range of cloud-centric IT services and specialized healthcare IT support. This includes the implementation, optimization, and integration of electronic health records (EHR) systems with community partners, comprehensive application managed services, and reliable public cloud-based backup and disaster recovery solutions. Its diverse client base spans healthcare providers, insurance carriers, pharmaceutical and life sciences firms, biotechnology companies, and medical device manufacturers. Established in 2019, Healthcare Triangle, Inc. operates out of Pleasanton, California, as a subsidiary of SecureKloud Technologies, Inc.

OneMedNet Corporation offers advanced solutions for clinical imaging. Their core product, iRWD, is an artificial intelligence-driven platform that securely anonymizes, searches for, and organizes imaging data. This system is utilized by their extensive network of medical and academic research institutions, with the goal of fostering significant progress in medical research, new discoveries, and diagnostic techniques across the broader field of life sciences. The company's operations are based out of Eden Prairie, Minnesota.

Perimeter Medical Imaging AI, Inc., established in 2013 and headquartered in Toronto, Canada, is a medical technology innovator. The company focuses on creating and marketing sophisticated imaging solutions that empower surgeons, radiologists, and pathologists to meticulously examine microscopic tissue details throughout clinical interventions. A cornerstone of their offerings is an advanced Optical Coherence Tomography (OCT) imaging system, providing clinicians with precise cross-sectional views of tissue up to a depth of 2 millimeters. This comprehensive system incorporates the S-series OCT, B-series OCT units, and a dedicated imaging console. Complementing this, Perimeter also provides ImgAssist, an artificial intelligence (AI) platform. This technology is engineered to streamline image review processes and, when integrated with their OCT system, serves as a powerful aid for physicians. It facilitates the real-time visualization and assessment of surgical margins, thereby enhancing patient outcomes and minimizing the necessity for subsequent operations. Furthermore, the company furnishes hospitals and specialized cancer treatment centers with its proprietary image library and consumable specimen containers.

Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.

Veradigm Inc. is a global healthcare technology enterprise that delivers cutting-edge information technology platforms to a diverse client base, including healthcare providers, health plans (payers), and biopharmaceutical companies, operating across the United States and various international markets. For healthcare providers, the company offers a suite of integrated solutions designed to optimize operations. These include Practice Management software, AI-driven Patient Scheduling tools, and systems for Electronic Statements and Payments. Veradigm also provides comprehensive revenue cycle management, encompassing specialized services and a dedicated clearinghouse to streamline financial workflows. Furthermore, their electronic health records (EHR) portfolio features advanced options like ePrescribe with EPCS, Veradigm HER, and Practice Fusion HER, complemented by a robust Patient Engagement Platform. The firm extends its offerings to network partners through a variety of connectivity solutions. These comprise API integration tools such as Veradigm Connect and Veradigm App Expo, a Diagnostic Ordering and Resulting Network, a Channel Partner Program, and Veradigm ePrescribe Enterprise. Health plans and payers benefit from Veradigm's specialized solutions, which include sophisticated risk adjustment tools like Health Equity Analytics, Risk Adjustment Analytics, Risk Mitigator, Comprehensive Submissions, and Utilization Analytics. They also provide quality management systems, including quality analytics and integrated risk adjustment and quality management features. Data exchange and coding solutions, such as eChart Courier, eChart Coder, and eChart Integration and Analytics, further enhance efficiency. Additionally, Veradigm offers provider engagement platforms like Veradigm Payer Insights and the comprehensive Veradigm Payerpath suite. For the biopharma sector, Veradigm supplies valuable real-world data solutions, including extensive health datasets and specialized registries for cardiology and metabolic conditions. This is coupled with real-world evidence platforms, such as the Real World Evidence Analytics Platform. Therapy-focused data is available for key areas like cardiovascular, central nervous system, metabolic, and immunology. The company also delivers Digital Health Media solutions. Established in 1986 and headquartered in Chicago, Illinois, Veradigm Inc. was previously known as Allscripts Healthcare Solutions, Inc., before rebranding to its current name in January 2023.

Xunfei Healthcare Technology Co., Ltd. provides healthcare AI solutions in the People's Republic of China. The company offers primary solutions, including a general practice clinical decision support system (CDSS) and chronic disease management, which enables identification of key populations, one-click chronic disease screening and risk stratification, dynamic health monitoring, smart task reminders, and decision support during service delivery. It also offers smart hospital solutions, including smart service, smart healthcare, smart medical treatment combination, as well as the iFlytek Xiaoyi APP, an AI health assistant. In addition, the company provides regional public health solutions and medical insurance administrative solutions. Further, the company provides the Xunfei Xiaoyi APP, an AI-driven post-discharge patient management system, and the Cloud Medical Imaging Platform, which offers remote consultation services; and digital imaging services. Additionally, it offers intelligent healthcare solutions, including a general practitioner assistant, grass-roots integrated intelligent information platform, family physician assistant, AI chronic disease management system, and a smart surveillance and early warning platform for infectious diseases. The company's intelligent hardware offerings include smart hearing aids and a smart sphygmomanometer. The company was formerly known as Anhui Xunfei Medical Co., Ltd. and changed its name to Xunfei Healthcare Technology Co., Ltd. in February 2023. The company was founded in 2016 and is headquartered in Hefei, the People's Republic of China.

DataMEDS AI is a Health IT company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units. The company incorporates its artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contacts platform PharmacyChain™ to optimize the prescription medicines reimbursement and dispensing journey.

Amesite Inc., a technology company, engages in the marketing and development of B2C and B2B AI-driven solutions in the United States. Its products include Amesite Engage, that leverages proprietary AI infrastructure, offering cutting-edge applications that cater to both individual and professional needs; and NurseMagic, mobile healthcare app, streamlines creation of nursing notes and documentation tasks, enhances patient communication, and offers personalized guidance to nurses on patient care, medications, and handling challenging workplace situation. Amesite Inc. was founded in 2017 and is headquartered in Detroit, Michigan.

Pathkey.AI Ltd is an Australian digital health firm that harnesses artificial intelligence (AI) to advance clinical trials and improve the predictability of patient outcomes, particularly within Australia. The company presents a suite of AI-driven solutions: TrialKey, a sophisticated platform for simulating and optimizing trial designs to boost success rates, and TrialGen, an AI-powered utility crafted to simplify the clinical trial design process. They extend their services to a diverse clientele, encompassing biopharmaceutical companies, MedTech innovators, governmental agencies, and various healthcare organizations. Established in Sydney in 1994, the entity known today as Pathkey.AI Ltd will formally change its name from Opyl Limited in August 2025.

Renalytix Plc specializes in developing cutting-edge in vitro diagnostic solutions for kidney diseases, leveraging the power of artificial intelligence. Their primary offering, KidneyIntelX, is an advanced diagnostic platform. It employs a sophisticated AI-enabled algorithm that synthesizes various data streams, such as scientifically validated blood biomarkers, inherited genetic factors, and personalized patient data extracted from electronic health record systems. The output is a unique, individualized risk score for each patient. These innovative tools serve multiple critical functions: they assist in the diagnosis and prognosis of kidney ailments, optimize clinical patient management, facilitate patient stratification for pharmaceutical clinical trials, and aid in the discovery of novel drug targets. The company has secured several pivotal license agreements. A partnership with Mount Sinai Health System grants rights for the development and commercialization of AI applications in kidney disease diagnostics. Another agreement with Joslin Diabetes Center, Inc. focuses on creating and marketing biomarker-based products for the diagnosis and prediction of kidney conditions. Furthermore, Renalytix holds a license with Kantaro Biosciences LLC for laboratory assays designed to detect SARS-CoV-2 antibodies. In a collaborative effort, Renalytix has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine. This alliance aims to implement an advanced clinical care paradigm, specifically designed to enhance kidney health and mitigate the progression of kidney disease and subsequent renal failure in high-risk patient populations. Founded in 2018, the company operated under the name Renalytix AI plc until its change to Renalytix Plc in June 2021. Its corporate headquarters are situated in New York, New York.

Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chemistry-focused computer program that forecasts molecular properties from structural inputs, alongside MedChem Designer, MonolixSuite, and PKPlus for additional modeling and simulation needs. Beyond software, the company extends its expertise through various services, including contract research for population modeling and simulation, specialized training and consultation to advance pharmacometrics studies, and clinical-pharmacology consulting to aid in regulatory submissions. Simulations Plus serves a broad spectrum of clients globally, including pharmaceutical, biotechnology, agrochemical, cosmetic, and food companies, as well as academic institutions and regulatory bodies. The company was founded in 1996 and maintains its headquarters in Lancaster, California.

Headquartered in Valbonne, France, Median Technologies S.A. was established in 2002. This company specializes in developing and commercializing advanced software and platforms designed for medical image analysis. Its reach extends globally, serving markets in France, the United States, Canada, the United Kingdom, China, and beyond. Among its key offerings is iBiops, an innovative, AI-powered software classified as a medical device. This solution comprehensively integrates and optimizes the entire medical imaging workflow. Additionally, Median Technologies provides iSee, a service dedicated to image analysis specifically for clinical trials. Furthermore, the company delivers extensive imaging contract research organization (CRO) services. These encompass a wide range of activities, from study initiation and the management of both image and clinical data, to scientific advisory, independent reviews, image data processing, site support, and final study close-out. Solidifying its commitment to research, Median Technologies maintains a collaborative agreement with the University of California.

Metis TechBio Co., Ltd., founded in 2020 and headquartered in Beijing, China, (previously Hangzhou Jitai Pharmaceutical Technology Co., Ltd.) specializes in the advanced research and development of AI-powered nanomaterials. The company's core mission is to facilitate the delivery and application of active agents within carbon-based life forms, operating in both the Chinese Mainland and the United States. Central to its offerings is NanoForge, a comprehensive suite of interconnected technologies that includes a novel lipid library, foundational artificial intelligence models, METiSAIAgent, cutting-edge quantum chemistry and molecular dynamics simulations, and AI-driven screening platforms. Furthermore, Metis TechBio has developed specialized platforms like AiTEM, AiLNP, and AiRNA. These tools are crucial for simulating, predicting, and interpreting interactions at the nanoscale, thereby enabling the precise design, optimization, and validation of sophisticated nanomaterials and their associated payloads. The company provides its services through a three-tiered system: a foundational dry-wet data layer supported by integrated laboratory infrastructure, a model layer featuring METiS AI foundational models, and an application layer known as METiSAgentv. Metis TechBio primarily serves a diverse clientele, including pharmaceutical companies, biotechnology firms, and medical research institutions.

ImExHS Limited delivers cloud-powered medical imaging technologies to customers worldwide, including those in Australia. The firm specializes in the development and sale of modular imaging software systems, which encompass comprehensive information management platforms for disciplines such as radiology, cardiology, and pathology, alongside a robust picture archiving and communication system (PACS). Its principal software solutions include AQUILA for radiology, ALULA for pathology, and Antero for cardiology. Moreover, ImExHS offers STELLA.I, a suite of artificial intelligence tools hosted in the cloud, crafted to bolster diagnostic capabilities for medical professionals. The company further extends outsourced radiology and teleradiology services to hospitals and various other healthcare entities. Established in 2001, ImExHS Limited operates from its base in Mascot, Australia.

Acer Medical Inc. is a company dedicated to the healthcare industry, providing advanced solutions that incorporate artificial intelligence, clinical data analysis, and specialized software. Their product lineup features VeriSee DR, an AI-powered diagnostic tool for detecting diabetic retinopathy; VeriSee AMD, an AI-enabled screening application focused on identifying age-related macular degeneration; and VeriOsteo OP, an AI-assisted screening software used to detect anomalies in bone mineral density. The company was established in 2018 and is headquartered in New Taipei City, Taiwan.

Enlitic, Inc., headquartered in Fort Collins, Colorado, is a company operating in the healthcare sector across the United States, Europe, and Japan. Specializing in artificial intelligence (AI), Enlitic develops sophisticated software solutions engineered to manage and optimize medical imaging data within radiology, covering modalities such as magnetic resonance imaging (MRI), computed tomography (CT) scans, and ultrasound. The company licenses these AI-powered solutions to both healthcare providers and original equipment manufacturers (OEMs). Its comprehensive suite of healthcare data solutions includes ENDEX, an AI platform designed to standardize diverse medical imaging data; ENCOG, an AI-enabled solution for data anonymization that effectively safeguards protected health information (PHI) while preserving crucial clinical insights in imaging studies; and Migratek, an AI-driven data migration solution, complemented by routing services. Enlitic's offerings are specifically tailored to support healthcare IT departments, hospital executives, and clinical researchers. Incorporated in 2014, the company was previously known as You Partners, Inc.

Established in 2004 and headquartered in Montpellier, France, Intrasense S.A. specializes in the global development of sophisticated software for visualizing and analyzing diverse medical imaging data, marketed under its Myrian brand. The company's offerings feature the Myrian Imaging Layer, a versatile multi-modality visualization platform tailored for professionals in the health industry. It also provides Myrian Studio, a dedicated development environment empowering innovators, industrial partners, spin-offs, and research institutions to build medical imaging applications. Furthermore, Intrasense leverages its Myrian technologies to facilitate the creation of biomarkers and artificial intelligence solutions. A key component of its product line is Myrian Clinical Apps, an extensive collection of advanced post-processing clinical applications. This portfolio encompasses specialized modules like Myrian XP-Breast, XP-Prostate, XP-Liver, XP-Mammo, XP-Lung, XP-Colon, XP-Vessel, and XP-Cardiac, alongside Myrian XL-Onco for tracking lesions. These applications, which also provide solutions for analyzing specific pathologies or organs, offer various tools for interpreting data from MRI, CT scans, conventional radiology, and nuclear imaging examinations.

Advanced Media, Inc. specializes in the creation, development, and implementation of advanced speech recognition solutions. Their proprietary AmiVoice technology forms the core of their product and service offerings. The company licenses a variety of software applications and delivers AmiVoice-powered services to a diverse clientele, encompassing both corporate entities and individual users. Their innovative solutions find widespread application, particularly within the medical sector for producing voice-controlled certificates and reports, and in customer service centers for transforming spoken interactions into actionable data. Additionally, Advanced Media provides tools for streamlining conference proceedings, assisting in mobile application development, improving language learning resources, and enhancing efficiency in manufacturing, distribution, and logistics. The company also furnishes comprehensive support and expert consulting services. Established in Tokyo, Japan, in 1997, Advanced Media, Inc. is headquartered there.

Pure-play AI vendor positioned to capture budget shifts away from legacy IT services.

GEHC is aggressively investing in AI (e.g., Sonic DL, AIR Recon DL) to maintain edge and workflow efficiency.

GE HealthCare is the direct recipient of the FDA clearance for MIM Contour ProtégéAI+ 2.0. The inclusion of a Predetermined Change Control Plan (PCCP) is a major strategic advantage, as it allows the company to iterate and update its AI models without the delay of new 510(k) submissions, accelerating its speed-to-market and enhancing its oncology and cardiology software portfolios.